{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ADME-Tox", "astragaloside IV", "blood\u2013brain barrier", "memory impairment", "passive avoidance"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38612831", "DateCompleted": {"Year": "2024", "Month": "04", "Day": "15"}, "DateRevised": {"Year": "2024", "Month": "04", "Day": "25"}, "Article": {"Language": ["eng"], "ELocationID": ["4021", "10.3390/ijms25074021"], "ArticleDate": [{"Year": "2024", "Month": "04", "Day": "04"}], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "25", "Issue": "7", "PubDate": {"Year": "2024", "Month": "Apr", "Day": "04"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Astragaloside IV as a Memory-Enhancing Agent: In Silico Studies with In Vivo Analysis and Post Mortem ADME-Tox Profiling in Mice.", "Abstract": {"AbstractText": ["Many people around the world suffer from neurodegenerative diseases associated with cognitive impairment. As life expectancy increases, this number is steadily rising. Therefore, it is extremely important to search for new treatment strategies and to discover new substances with potential neuroprotective and/or cognition-enhancing effects. This study focuses on investigating the potential of astragaloside IV (AIV), a triterpenoid saponin with proven acetylcholinesterase (AChE)-inhibiting activity naturally occurring in the root of <i>Astragalus mongholicus</i>, to attenuate memory impairment. Scopolamine (SCOP), an antagonist of muscarinic cholinergic receptors, and lipopolysaccharide (LPS), a trigger of neuroinflammation, were used to impair memory processes in the passive avoidance (PA) test in mice. This memory impairment in SCOP-treated mice was attenuated by prior intraperitoneal (ip) administration of AIV at a dose of 25 mg/kg. The attenuation of memory impairment by LPS was not observed. It can therefore be assumed that AIV does not reverse memory impairment by anti-inflammatory mechanisms, although this needs to be further verified. All doses of AIV tested did not affect baseline locomotor activity in mice. In the post mortem analysis by mass spectrometry of the body tissue of the mice, the highest content of AIV was found in the kidneys, then in the spleen and liver, and the lowest in the brain."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Physical Chemistry, Institute of Chemical Sciences, Faculty of Chemistry, Maria Curie-Sk\u0142odowska University in Lublin, Pl. M. Curie-Sk\u0142odowskiej 3, 20-031 Lublin, Poland."}, {"Identifier": [], "Affiliation": "Department of Pharmacognosy with Medicinal Plants Garden, Medical University of Lublin, 1 Chodzki St., 20-093 Lublin, Poland."}], "LastName": "St\u0119pnik", "ForeName": "Katarzyna", "Initials": "K"}, {"Identifier": ["0000-0001-7076-600X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy with Medicinal Plants Garden, Medical University of Lublin, 1 Chodzki St., 20-093 Lublin, Poland."}], "LastName": "Kukula-Koch", "ForeName": "Wirginia", "Initials": "W"}, {"Identifier": ["0000-0003-2203-1636"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Chemistry, Medical University of Lublin, 4A Chod\u017aki St., 20-093 Lublin, Poland."}], "LastName": "Boguszewska-Czubara", "ForeName": "Anna", "Initials": "A"}, {"Identifier": ["0000-0001-8857-847X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Experimental and Clinical Pharmacology, Medical University of Lublin, 8B Jaczewskiego St., 20-090 Lublin, Poland."}], "LastName": "Gawel", "ForeName": "Kinga", "Initials": "K"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "3A592W8XKE", "NameOfSubstance": "astragaloside A"}, {"RegistryNumber": "EC 3.1.1.7", "NameOfSubstance": "Acetylcholinesterase"}, {"RegistryNumber": "0", "NameOfSubstance": "Saponins"}, {"RegistryNumber": "0", "NameOfSubstance": "Triterpenes"}, {"RegistryNumber": "0", "NameOfSubstance": "Lipopolysaccharides"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Acetylcholinesterase"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Saponins"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Triterpenes"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Memory Disorders"}, {"QualifierName": ["toxicity"], "DescriptorName": "Lipopolysaccharides"}], "CoiStatement": "The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "World Health Organization  Global Action Plan on the Public Health Response to Dementia 2017\u20132025. 2017.  [(accessed on 10 April 2023)].  Available online:  https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025."}, {"Citation": "Hullinger R., Puglielli L. Molecular and cellular aspects of age-related cognitive decline and Alzheimer\u2019s disease. Behav. Brain Res. 2017;322:191\u2013205. doi: 10.1016/j.bbr.2016.05.008.", "ArticleIdList": ["10.1016/j.bbr.2016.05.008", "PMC5099115", "27163751"]}, {"Citation": "Kluever V., Fornasiero E.F. Principles of brain aging: Status and challenges of modeling human molecular changes in mice. Ageing Res. Rev. 2021;72:101465. doi: 10.1016/j.arr.2021.101465.", "ArticleIdList": ["10.1016/j.arr.2021.101465", "34555542"]}, {"Citation": "Chu W., Phan C.W., Lim S.J., Babji A.S. Insights on the molecular mechanism of neuroprotection exerted by edible bird\u2019s nest and its bioactive constituents. Food Sci. Hum. Wellness. 2023;12:1008\u20131019. doi: 10.1016/j.fshw.2022.10.021.", "ArticleIdList": ["10.1016/j.fshw.2022.10.021"]}, {"Citation": "Farooqui A.A. Contribution of neuroinflammation, resolution, and neuroprotection in neurotraumatic diseases. In: Farooqui A.A., editor. Neuroinflammation, Resolution, and Neuroprotection in the Brain. Elsevier; Amsterdam, The Netherlands: 2022. pp. 83\u2013119."}, {"Citation": "Rapposelli S., Digiacomo M., Balsamo A. P-gp Transporter and its Role in Neurodegenerative Diseases. Curr. Top. Med. Chem. 2009;9:209\u2013217. doi: 10.2174/156802609787521544.", "ArticleIdList": ["10.2174/156802609787521544", "19200006"]}, {"Citation": "Elufioye T.O., Berida T.I., Habtemariam S. Plants-Derived Neuroprotective Agents: Cutting the Cycle of Cell Death through Multiple Mechanisms. Evid. Based Complement. Alternat. Med. 2017;2017:3574012. doi: 10.1155/2017/3574012.", "ArticleIdList": ["10.1155/2017/3574012", "PMC5585568", "28904554"]}, {"Citation": "Selkoe D.J. Alzheimer\u2019s Disease: Genes, proteins, and therapy. Physiol. Rev. 2001;81:741\u2013766. doi: 10.1152/physrev.2001.81.2.741.", "ArticleIdList": ["10.1152/physrev.2001.81.2.741", "11274343"]}, {"Citation": "Arriagada P.V., Marzloff K., Hyman B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer\u2019s disease. Neurology. 1992;42:1681\u20131688. doi: 10.1212/WNL.42.9.1681.", "ArticleIdList": ["10.1212/WNL.42.9.1681", "1307688"]}, {"Citation": "Mrak R.E., Griffin W.S.T. Interleukin-1, neuroinflammation, and Alzheimer\u2019s disease. Neurobiol. Aging. 2001;22:903\u2013908. doi: 10.1016/S0197-4580(01)00287-1.", "ArticleIdList": ["10.1016/S0197-4580(01)00287-1", "11754997"]}, {"Citation": "Cole G., Teter B., Frautschy S. Neuroprotective effects of curcumin. Adv. Exp. Med. Biol. 2007;595:197\u2013212. doi: 10.1007/978-0-387-46401-5_8.", "ArticleIdList": ["10.1007/978-0-387-46401-5_8", "PMC2527619", "17569212"]}, {"Citation": "Garcia-Alloza M., Dodwell S.A., Borrelli L.A., Raju S., Bacskai B. In vivo reduction of plaque size in APPswe/PS1D9 mice treated with curcumin. Alzheimer\u2019s Dement. 2006;2:S617. doi: 10.1016/j.jalz.2006.05.2083.", "ArticleIdList": ["10.1016/j.jalz.2006.05.2083"]}, {"Citation": "Hampel H., Mesulam M.M., Cuello A.C., Farlow M.R., Giacobini E., Grossberg G.T., Khachaturian A.S., Vergallo A., Cavedo E., Snyder P.J., et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141:1917\u20131933. doi: 10.1093/brain/awy132.", "ArticleIdList": ["10.1093/brain/awy132", "PMC6022632", "29850777"]}, {"Citation": "Houser C.R., Crawford G.D., Barber R.P., Salvaterra P.M., Vaughn J.E. Organization and morphological characteristics of cholinergic neurons: An immunocytochemical study with a monoclonal antibody to choline acetyltransferase. Brain Res. 1983;266:97\u2013119. doi: 10.1016/0006-8993(83)91312-4.", "ArticleIdList": ["10.1016/0006-8993(83)91312-4", "6850348"]}, {"Citation": "Woolf N.J., Butcher L.L. Cholinergic systems mediate action from movement to higher consciousness. Behav. Brain Res. 2011;221:488\u2013498. doi: 10.1016/j.bbr.2009.12.046.", "ArticleIdList": ["10.1016/j.bbr.2009.12.046", "20060422"]}, {"Citation": "Woolf N.J. Cholinergic systems in mammalian brain and spinal cord. Prog. Neurobiol. 1991;37:475\u2013524. doi: 10.1016/0301-0082(91)90006-M.", "ArticleIdList": ["10.1016/0301-0082(91)90006-M", "1763188"]}, {"Citation": "Ferreira-Vieira T.H., Guimaraes I.M., Silva F.R., Ribeiro F.M. Alzheimer\u2019s disease: Targeting the Cholinergic System. Curr. Neuropharmacol. 2016;14:101\u2013115. doi: 10.2174/1570159X13666150716165726.", "ArticleIdList": ["10.2174/1570159X13666150716165726", "PMC4787279", "26813123"]}, {"Citation": "Pepeu G., Giovannini M.G. The fate of the brain cholinergic neurons in neurodegenerative diseases. Brain Res. 2017;1670:173\u2013184. doi: 10.1016/j.brainres.2017.06.023.", "ArticleIdList": ["10.1016/j.brainres.2017.06.023", "28652219"]}, {"Citation": "Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011;221:555\u2013563. doi: 10.1016/j.bbr.2010.11.058.", "ArticleIdList": ["10.1016/j.bbr.2010.11.058", "21145918"]}, {"Citation": "Dunnett S.B., Everitt B.J., Robbins T.W. The basal forebraincortical cholinergic system: Interpreting the functional consequences of excitotoxic lesions. Trends Neurosci. 1991;14:494\u2013501. doi: 10.1016/0166-2236(91)90061-X.", "ArticleIdList": ["10.1016/0166-2236(91)90061-X", "1726766"]}, {"Citation": "Hasselmo M.E., Anderson B.P., Bower J.M. Cholinergic modulation of cortical associative memory function. J. Neurophysiol. 1992;67:1230\u20131246. doi: 10.1152/jn.1992.67.5.1230.", "ArticleIdList": ["10.1152/jn.1992.67.5.1230", "1597709"]}, {"Citation": "Lucas-Meunier E., Fossier P., Baux G., Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Arch. 2003;446:17\u201329. doi: 10.1007/s00424-002-0999-2.", "ArticleIdList": ["10.1007/s00424-002-0999-2", "12690458"]}, {"Citation": "Sarter M., Bruno J.P. Cognitive functions of cortical acetylcholine: Toward a unifying hypothesis. Brain Res. Rev. 1997;23:28\u201346. doi: 10.1016/S0165-0173(96)00009-4.", "ArticleIdList": ["10.1016/S0165-0173(96)00009-4", "9063585"]}, {"Citation": "Bucci D.J., Holland P.C., Gallagher M. Removal of cholinergic input to rat posterior parietal cortex disrupts incremental processing of conditioned stimuli. J. Neurosci. 1998;18:8038\u20138046. doi: 10.1523/JNEUROSCI.18-19-08038.1998.", "ArticleIdList": ["10.1523/JNEUROSCI.18-19-08038.1998", "PMC6793033", "9742170"]}, {"Citation": "Voytko M.L., Olton D.S., Richardson R.T., Gorman L.K., Tobin J.R., Price D.L. Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J. Neurosci. 1994;14:167\u2013186. doi: 10.1523/JNEUROSCI.14-01-00167.1994.", "ArticleIdList": ["10.1523/JNEUROSCI.14-01-00167.1994", "PMC6576852", "8283232"]}, {"Citation": "Pepeu G., Giovannini M.G., Bracco L. Effect of cholinesterase inhibitors on attention. Chem. Biol. Interact. 2013;203:361\u2013364. doi: 10.1016/j.cbi.2012.09.016.", "ArticleIdList": ["10.1016/j.cbi.2012.09.016", "23047023"]}, {"Citation": "Bracco L., Bessi V., Padiglioni S., Marini S., Pepeu G. Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer\u2019s disease patients. J. Alzheimers Dis. 2014;40:737\u2013742. doi: 10.3233/JAD-131154.", "ArticleIdList": ["10.3233/JAD-131154", "24577458"]}, {"Citation": "Kim D.H., Jeon S.J., Jung J.W., Lee S., Yoon B.H., Shin B.Y., Son K.H., Cheong J.H., Kim Y.S., Kang S.S., et al. Tanshinone congeners improve memory impairments induced by scopolamine on passive avoidance tasks in mice. Eur. J. Pharmacol. 2007;574:140\u2013147. doi: 10.1016/j.ejphar.2007.07.042.", "ArticleIdList": ["10.1016/j.ejphar.2007.07.042", "17714702"]}, {"Citation": "St\u0119pnik K., Kukula-Koch W., Plazinski W., Gawel K., Gawe\u0142-B\u0119ben K., Khurelbat D., Boguszewska-Czubara A. Significance of Astragaloside IV from the Roots of Astragalus mongholicus as an Acetylcholinesterase Inhibitor-From the Computational and Biomimetic Analyses to the In Vitro and In Vivo Studies of Safety. Int. J. Mol. Sci. 2023;24:9152. doi: 10.3390/ijms24119152.", "ArticleIdList": ["10.3390/ijms24119152", "PMC10252989", "37298103"]}, {"Citation": "St\u0119pnik K., Kukula-Koch W. In Silico Studies on Triterpenoid Saponins Permeation through the Blood-Brain Barrier Combined with Postmortem Research on the Brain Tissues of Mice Affected by Astragaloside IV Administration. Int. J. Mol. Sci. 2020;21:2534. doi: 10.3390/ijms21072534.", "ArticleIdList": ["10.3390/ijms21072534", "PMC7177733", "32260588"]}, {"Citation": "van Breemen R.B., Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin. Drug Metab. Toxicol. 2005;1:175\u2013185. doi: 10.1517/17425255.1.2.175.", "ArticleIdList": ["10.1517/17425255.1.2.175", "16922635"]}, {"Citation": "DiMarco R.L., Hunt D.R., Dewi R.E., Heilshorn S.C. Improvement of paracellular transport in the Caco-2 drug screening model using protein-engineered substrates. Biomaterials. 2017;129:152\u2013162. doi: 10.1016/j.biomaterials.2017.03.023.", "ArticleIdList": ["10.1016/j.biomaterials.2017.03.023", "PMC5572671", "28342321"]}, {"Citation": "Anastas P., Eghbali N. Green chemistry: Principles and practice. Chem. Soc. Rev. 2010;39:301\u2013312. doi: 10.1039/B918763B.", "ArticleIdList": ["10.1039/B918763B", "20023854"]}, {"Citation": "Ekins S., Waller C.L., Swaan P.W., Cruciani G., Wrighton S.A., Wikel J.H. Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods. 2000;44:251\u2013272. doi: 10.1016/S1056-8719(00)00109-X.", "ArticleIdList": ["10.1016/S1056-8719(00)00109-X", "11274894"]}, {"Citation": "Wilson F.A., Dietschy J.M. The intestinal unstirred layer: Its surface area and effect on active transport kinetics. Biochim. Biophys. Acta. 1974;363:112\u2013126. doi: 10.1016/0005-2736(74)90010-8.", "ArticleIdList": ["10.1016/0005-2736(74)90010-8", "4854915"]}, {"Citation": "Wils P., Warnery A., Phung-Ba V., Legrain S., Scherman D. High lipophilicity decreases drug transport across intestinal epithelial cells. J. Pharmacol. Exp. Ther. 1994;269:654\u2013658.", "ArticleIdList": ["8182532"]}, {"Citation": "Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 1996;22:67\u201384. doi: 10.1016/S0169-409X(96)00415-2.", "ArticleIdList": ["10.1016/S0169-409X(96)00415-2", "11259831"]}, {"Citation": "New R. Oral Delivery of Biologics via the Intestine. Pharmaceutics. 2020;13:18. doi: 10.3390/pharmaceutics13010018.", "ArticleIdList": ["10.3390/pharmaceutics13010018", "PMC7824380", "33374222"]}, {"Citation": "Kim W.S., Weickert C.S., Garner B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J. Neurochem. 2008;104:1145\u20131166. doi: 10.1111/j.1471-4159.2007.05099.x.", "ArticleIdList": ["10.1111/j.1471-4159.2007.05099.x", "17973979"]}, {"Citation": "Tatsuta T., Naito M., Oh-hara T., Sugawara I., Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 1992;267:20383\u201320391. doi: 10.1016/S0021-9258(19)88713-6.", "ArticleIdList": ["10.1016/S0021-9258(19)88713-6", "1356979"]}, {"Citation": "Didziapetris R., Japertas P., Avdeef A., Petrauskas A. Classification Analysis of P-Glycoprotein Substrate Specificity. J. Drug Target. 2003;11:391\u2013406. doi: 10.1080/10611860310001648248.", "ArticleIdList": ["10.1080/10611860310001648248", "15203928"]}, {"Citation": "Lochner M., Thompson A.J. The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors. Neuropharmacology. 2016;108:220\u2013228. doi: 10.1016/j.neuropharm.2016.04.027.", "ArticleIdList": ["10.1016/j.neuropharm.2016.04.027", "PMC4920643", "27108935"]}, {"Citation": "Misane I., \u00d6gren S. Selective 5-HT1A Antagonists WAY 100635 and NAD-299 Attenuate the Impairment of Passive Avoidance Caused by Scopolamine in the Rat. Neuropsychopharmacology. 2003;28:253\u2013264. doi: 10.1038/sj.npp.1300024.", "ArticleIdList": ["10.1038/sj.npp.1300024", "12589378"]}, {"Citation": "Araujo D.M., Lapchak P.A., Robitaille Y., Gauthier S., Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer\u2019s disease. J. Neurochem. 1988;50:1914\u20131923. doi: 10.1111/j.1471-4159.1988.tb02497.x.", "ArticleIdList": ["10.1111/j.1471-4159.1988.tb02497.x", "3373218"]}, {"Citation": "DeKosky S.T., Scheff S.W., Styren S.D. Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration. 1996;5:417\u2013421. doi: 10.1006/neur.1996.0056.", "ArticleIdList": ["10.1006/neur.1996.0056", "9117556"]}, {"Citation": "Kuhl D.E., Koeppe R.A., Minoshima S., Snyder S.E., Ficaro E.P., Foster N.L. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer\u2019s disease. Neurology. 1999;52:691\u2013699. doi: 10.1212/WNL.52.4.691.", "ArticleIdList": ["10.1212/WNL.52.4.691", "10078712"]}, {"Citation": "Shinotoh H., Namba H., Fukushi K., Nagatsuka S., Tanaka N., Aotsuka A. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer\u2019s disease: A positron emission tomography study. Ann. Neurol. 2000;48:194\u2013200. doi: 10.1002/1531-8249(200008)48:2<194::AID-ANA9>3.0.CO;2-X.", "ArticleIdList": ["10.1002/1531-8249(200008)48:2<194::AID-ANA9>3.0.CO;2-X", "10939570"]}, {"Citation": "Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 2000;163:495\u2013529. doi: 10.1006/exnr.2000.7397.", "ArticleIdList": ["10.1006/exnr.2000.7397", "10833325"]}, {"Citation": "Bartolomeo A.C., Morris H., Buccafusco J.J., Kille N., Rosenzweig-Lipson S., Husbands M.G., Sabb A.L., Abou-Gharbia M., Moyer J.A., Boast C.A. The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. J. Pharmacol. Exp. Ther. 2000;292:584\u2013596.", "ArticleIdList": ["10640295"]}, {"Citation": "Elrod K., Buccafusco J.J. An evaluation of the mechanism of scopolamine-induced impairment in two passive avoidance protocols. Pharmacol. Biochem. Behav. 1988;29:15\u201321. doi: 10.1016/0091-3057(88)90267-5.", "ArticleIdList": ["10.1016/0091-3057(88)90267-5", "3353420"]}, {"Citation": "Blin O., Audebert C., Pitel S., Kaladjian A., Casse-Perrot C., Zaim M., Micallef J., Tisne-Versailles J., Sokoloff P., Chopin P., et al. Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: Evidence from preclinical and clinical studies. Psychopharmacol. Berl. 2009;207:201\u2013212. doi: 10.1007/s00213-009-1648-7.", "ArticleIdList": ["10.1007/s00213-009-1648-7", "19756528"]}, {"Citation": "Blotnick-Rubin E., Anglister L. Fine Localization of Acetylcholinesterase in the Synaptic Cleft of the Vertebrate Neuromuscular Junction. Front. Mol. Neurosci. 2018;11:123. doi: 10.3389/fnmol.2018.00123.", "ArticleIdList": ["10.3389/fnmol.2018.00123", "PMC5917012", "29725289"]}, {"Citation": "Gawel K., Labuz K., Gibula-Bruzda E., Jenda M., Marszalek-Grabska M., Silberring J., Kotlinska J.H. Acquisition and reinstatement of ethanol-induced conditioned place preference in rats: Effects of the cholinesterase inhibitors donepezil and rivastigmine. J Psychopharmacol. 2016;30:676\u2013687. doi: 10.1177/0269881116642539.", "ArticleIdList": ["10.1177/0269881116642539", "27097732"]}, {"Citation": "Gawel K., Gibula-Bruzda E., Dziedzic M., Jenda-Wojtanowska M., Marszalek-Grabska M., Silberring J., Kotlinska J.H. Cholinergic activation affects the acute and chronic antinociceptive effects of morphine. Physiol. Behav. 2017;169:22\u201332. doi: 10.1016/j.physbeh.2016.11.011.", "ArticleIdList": ["10.1016/j.physbeh.2016.11.011", "27865771"]}, {"Citation": "Batista C.R.A., Gomes G.F., Candelario-Jalil E., Fiebich B.L., de Oliveira A.C.P. Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration. Int. J. Mol. Sci. 2019;20:2293. doi: 10.3390/ijms20092293.", "ArticleIdList": ["10.3390/ijms20092293", "PMC6539529", "31075861"]}, {"Citation": "Marcucci H., Paoletti L., Jackowski S., Banchio C. Phosphatidylcholine biosynthesis during neuronal differentiation and its role in cell fate determination. J. Biol. Chem. 2010;285:25382\u201325393. doi: 10.1074/jbc.M110.139477.", "ArticleIdList": ["10.1074/jbc.M110.139477", "PMC2919101", "20525991"]}, {"Citation": "Lewis S.M., Williams A., Eisenbarth S.C. Structure and function of the immune system in the spleen. Sci. Immunol. 2019;4:eaau6085. doi: 10.1126/sciimmunol.aau6085.", "ArticleIdList": ["10.1126/sciimmunol.aau6085", "PMC6495537", "30824527"]}, {"Citation": "Yao J., Liu J., He Y., Liu L., Xu Z., Lin X., Liu N., Kai G. Systems pharmacology reveals the mechanism of Astragaloside IV in improving immune activity on cyclophosphamide-induced immunosuppressed mice. J. Ethnopharmacol. 2023;313:116533. doi: 10.1016/j.jep.2023.116533.", "ArticleIdList": ["10.1016/j.jep.2023.116533", "37100262"]}, {"Citation": "Liu R., Jiang H., Tian Y., Zhao W., Wu X. Astragaloside IV protects against polymicrobial sepsis through inhibiting inflammatory response and apoptosis of lymphocytes. J. Surg. Res. 2016;200:315\u2013323. doi: 10.1016/j.jss.2015.08.024.", "ArticleIdList": ["10.1016/j.jss.2015.08.024", "26375505"]}, {"Citation": "Zhang W.-D., Zhang C., Liu R.-H., Li H.-L., Zhang J.-T., Mao C., Moran S., Chen C.-L. Preclinical pharmacokinetics and tissue distribution of a natural cardioprotective agent astragaloside IV in rats and dogs. Life Sci. 2006;79:808\u2013815. doi: 10.1016/j.lfs.2006.02.032.", "ArticleIdList": ["10.1016/j.lfs.2006.02.032", "16564551"]}, {"Citation": "Feher M., Sourial E., Schmidt J.M. A simple model for the prediction of blood-brain partitioning. Int. J. Pharm. 2000;201:239\u2013247. doi: 10.1016/S0378-5173(00)00422-1.", "ArticleIdList": ["10.1016/S0378-5173(00)00422-1", "10878329"]}, {"Citation": "Liu R., Sun H., So S.-S. Development of quantitative structure\u2212property relationship models for early ADME evaluation in drug discovery. 2. Blood-brain barrier penetration. J Chem. Inf. Comput. Sci. 2001;41:1623\u20131632. doi: 10.1021/ci010290i.", "ArticleIdList": ["10.1021/ci010290i", "11749589"]}, {"Citation": "Van de Waterbeemd H. In Silico Models to Predict Oral Absorption. In: Taylor J.B., Triggle D.J., editors. Comprehensive Medicinal Chemistry, II. Elsevier; Amsterdam, The Netherlands: 2007. pp. 669\u2013697."}, {"Citation": "Fischer H., Gottschlich R., Seelig A. Blood-brain barrier permeation: Molecular parameters governing passive diffusion. J. Membr. Biol. 1998;165:201\u2013211. doi: 10.1007/s002329900434.", "ArticleIdList": ["10.1007/s002329900434", "9767674"]}, {"Citation": "Muehlbacher M., Spitzer G.M., Liedl K.R., Kornhuber J. Qualitative prediction of blood-brain barrier permeability on a large and refined dataset. J. Comput. Aided Mol. Des. 2011;25:1095\u20131106. doi: 10.1007/s10822-011-9478-1.", "ArticleIdList": ["10.1007/s10822-011-9478-1", "PMC3241963", "22109848"]}, {"Citation": "Hutter M.C. Prediction of blood-brain barrier permeation using quantum chemically derived information. J. Comput. Aided Mol. Des. 2003;17:415\u2013433. doi: 10.1023/A:1027359714663.", "ArticleIdList": ["10.1023/A:1027359714663", "14677638"]}, {"Citation": "Kotlinska J.H., Lopatynska-Mazurek M., Gawel K., Gabka P., Jenda-Wojtanowska M., Kruk-Slomka M., Marszalek-Grabska M., Danilczuk Z., Kedzierska E., Talarek S., et al. Impact of the metabotropic glutamate receptor7 (mGlu7) allosteric agonist, AMN082, on fear learning and memory and anxiety-like behavior. Eur. J. Pharmacol. 2019;858:172512. doi: 10.1016/j.ejphar.2019.172512.", "ArticleIdList": ["10.1016/j.ejphar.2019.172512", "31260653"]}, {"Citation": "Marszalek-Grabska M., Zakrocka I., Budzynska B., Marciniak S., Kaszubska K., Lemieszek M.K., Winiarczyk S., Kotlinska J.H., Rzeski W., Turski W.A. Binge-like mephedrone treatment induces memory impairment concomitant with brain kynurenic acid reduction in mice. Toxicol. Appl. Pharmacol. 2022;454:116216. doi: 10.1016/j.taap.2022.116216.", "ArticleIdList": ["10.1016/j.taap.2022.116216", "36057403"]}]}], "History": [{"Year": "2024", "Month": "3", "Day": "12"}, {"Year": "2024", "Month": "3", "Day": "30"}, {"Year": "2024", "Month": "4", "Day": "2"}, {"Year": "2024", "Month": "4", "Day": "15", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "4", "Day": "13", "Hour": "10", "Minute": "43"}, {"Year": "2024", "Month": "4", "Day": "13", "Hour": "1", "Minute": "16"}, {"Year": "2024", "Month": "4", "Day": "4"}], "PublicationStatus": "epublish", "ArticleIdList": ["38612831", "PMC11012721", "10.3390/ijms25074021", "ijms25074021"]}}]}